Blog
Octus on Credit: JP Morgan LevFin Conference forecasts a growing market
Geoff Burrows, Assistant Editor, Americas
Last week leveraged finance bankers, lawyers and investors descended on Miami for the annual JP Morgan Leveraged Finance Conference. We learned of some big deals coming in the pipeline, but were told not to expect a surge of new money until the second half of the year owing to a muted M&A environment and tariff and political uncertainty.
Takeaways include the bank suggesting spreads will stay tight for the next 12 to 24 months and see the market growing about $70 billion in total issuance this year. Leveraged credit will grow as a whole, with almost $50 billion in new issuance, dominated by loans. Private Credit and LMEs were also prominent features of the South Beach conference.
One name that dominated conference chatter was Bausch Health. After the company presented on Monday morning and held one on ones with investors, Octus learned JP Morgan was leading a deal to refinance Bausch’s near term debt and stabilize its long term operations. The deal, which could be to the tune of $5 billion, is expected to hit the market soon, and based on on the ground feedback from investors, should do well in what might be a remarkable turnaround for the pharma giant.
In addition to Bausch Health, last week Octus subscribers got the early scoop on multibillion-dollar financing deals for Novolex and Walgreens.
As new deals hit the market, you can expect more scoops and updates from Octus on the deal pipeline this year.
To receive these insights in real-time, sign up to receive Octus on Credit
This publication has been prepared by Octus, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2025 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.